Literature DB >> 19445800

Dystonia.

Ailsa Snaith1, Derick Wade.   

Abstract

INTRODUCTION: Dystonia is usually a lifelong condition with persistent pain and disability. Focal dystonia affects a single part of the body; generalised dystonia can affect most or all of the body. It is more common in women, and some types of dystonia are more common in people of European Ashkenazi Jewish descent. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments, surgical treatments, and physical treatments for focal, and for generalised dystonia? We searched: Medline, Embase, The Cochrane Library, and other important databases up to July 2007 (BMJ Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 13 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: acetylcholine receptor inhibitors, acupuncture, anticholinergic drugs, anticonvulsants, atypical antipsychotic drugs, benzodiazepines, biofeedback, botulinum toxin, chiropractic manipulation, deep brain stimulation of thalamus and globus pallidus, dopaminergic agonists and antagonists, gamma-aminobutyric acid (GABA) inhibitors, microvascular decompression, myectomy, occupational therapy, osteopathy, pallidotomy, physiotherapy, selective peripheral denervation, serotonergic agonists and antagonists, speech therapy, and thalamotomy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19445800      PMCID: PMC2907934     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  25 in total

1.  Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.

Authors:  D Ranoux; C Gury; J Fondarai; J L Mas; M Zuber
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

2.  Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.

Authors:  Ulrike Laubis-Herrmann; Katja Fries; Helge Topka
Journal:  Eur Neurol       Date:  2002       Impact factor: 1.710

3.  Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up.

Authors:  J J M Kruisdijk; J H T M Koelman; B W Ongerboer de Visser; R J de Haan; J D Speelman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-21       Impact factor: 10.154

4.  Reliability of the Burke-Fahn-Marsden scale in a multicenter trial for dystonia.

Authors:  Pierre Krystkowiak; Sophie Tezenas du Montcel; Laurent Vercueil; Jean-Luc Houeto; Christelle Lagrange; Philippe Cornu; Serge Blond; Alim-Louis Benabid; Pierre Pollak; Marie Vidailhet
Journal:  Mov Disord       Date:  2007-04-15       Impact factor: 10.338

5.  Sex-related influences on the frequency and age of onset of primary dystonia. Epidemiologic Study of Dystonia in Europe (ESDE) Collaborative Group.

Authors: 
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

6.  A prevalence study of primary dystonia in eight European countries.

Authors: 
Journal:  J Neurol       Date:  2000-10       Impact factor: 4.849

7.  How to assess motor impairment in writer's cramp.

Authors:  Kirsten E Zeuner; Martin Peller; Arne Knutzen; Iris Holler; Alexander Münchau; Mark Hallett; Günther Deuschl; Hartwig R Siebner
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

8.  Pallidal deep-brain stimulation in primary generalized or segmental dystonia.

Authors:  Andreas Kupsch; Reiner Benecke; Jörg Müller; Thomas Trottenberg; Gerd-Helge Schneider; Werner Poewe; Wilhelm Eisner; Alexander Wolters; Jan-Uwe Müller; Günther Deuschl; Marcus O Pinsker; Inger Marie Skogseid; Geir Ketil Roeste; Juliane Vollmer-Haase; Angela Brentrup; Martin Krause; Volker Tronnier; Alfons Schnitzler; Jürgen Voges; Guido Nikkhah; Jan Vesper; Markus Naumann; Jens Volkmann
Journal:  N Engl J Med       Date:  2006-11-09       Impact factor: 91.245

Review 9.  Dystonia: genetics and treatment update.

Authors:  Roongroj Bhidayasiri
Journal:  Neurologist       Date:  2006-03       Impact factor: 1.398

Review 10.  Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review.

Authors:  Christopher Watts; Chad Nye; Renata Whurr
Journal:  Clin Rehabil       Date:  2006-02       Impact factor: 3.477

View more
  2 in total

1.  Spectral EMG Changes in Cervical Dystonia Patients and the Influence of Botulinum Toxin Treatment.

Authors:  S W R Nijmeijer; E de Bruijn; R Verhagen; P A Forbes; D J Kamphuis; R Happee; M A J Tijssen; J H T M Koelman
Journal:  Toxins (Basel)       Date:  2017-08-23       Impact factor: 4.546

2.  Carbamazepine-induced dystonia in an adolescent.

Authors:  Shwetank Bansal; Manpreet Gill; Chhavi Bhasin
Journal:  Indian J Pharmacol       Date:  2016 May-Jun       Impact factor: 1.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.